LDS/Medical Tests/Fibroblast Growth Factor Receptor 3 (FGFR3) Mutation Analysis in Bladder Cancer

Fibroblast Growth Factor Receptor 3 (FGFR3) Mutation Analysis in Bladder Cancer

Bladder cancer is the second most common genitourinary tumor, the fourth most common cancer in men, and the eighth most common cancer in women over the age of 40. Typically bladder cancer is a noninvasive superficial cancer. Ninety percent of bladder cancer cases are classified as transitional cell carcinomas (TCC), while the remaining 10% are predominantly squamous cell or adenocarcinomas. 

TCC is classified as either being low grade or high grade, which can also be divided into superficially invasive (non-muscle invasive) or muscle invasive cancer. At presentation, a majority of bladder tumors (70%–80%) are superficially invasive low-grade bladder cancers (e.g., pTa, pT1 or pTIS), of which 50 to 80% will have one or several recurrences, and 15 to 25% will progress to muscle invasive tumors. For this reason, patients with “superficial” bladder cancer are regularly monitored for tumor recurrence and progression with cystoscopy and sometimes urine cytology. Cystoscopy examination of the bladder, and often urine cytology, are also standard care for patients >40 years of age presenting with hematuria. 

There are several tumorigenic changes that cause bladder cancer. The most common genetic abnormality in bladder cancer is a genetic mutation in the fibroblast growth factor receptor 3 (FGFR3) gene. FGFR3 is a receptor tyrosine kinase implicated in the tumorigenesis of multiple malignancies, including bladder and other urothelial cancers, multiple myeloma, and cervical cancer. In urothelial carcinoma, mutation in FGFR3 results in receptor activation in the extracellular domain, thereby resulting in dimerization and increased and sometimes continued tyrosine kinase activity. In addition to an activating mutation of FGFR3, the overexpression of the receptor due to gene translocation is another cause of bladder cancer.

It has been shown that activating mutations of FGFR3 have been associated with up to 70% of non-muscle-invasive bladder tumors, while overexpression of a wild-type receptor has been associated with more than 40% of tumors. The latter mutation has been correlated with more invasive disease. Activating mutations in the FGFR3 gene have been found in exons 7, 10 and 15 of the FGFR3 gene, which lead to increased FGFR3 tyrosine kinase activity, leading to increased and uncontrolled cell proliferation leading to the formation of bladder tumors. The most common mutations of FGFR3 with the prevalence percentage are listed in the table below.

Known mutations in bladder cancer

Codon Nucleotide Change Observed Frequency in Bladder Cancer Exon
R248C C>T 8–11% 7
S249C C>G 50–70% 7
G372C G>T 5–7% 10
S373C A>T <4% 10
Y375C A>G 10–22% 10
G382R G>A <3% 10
A393E C>A <2% 10
K652E/Q A>G/C <4% 15
K652M/T A>T/C <1% 15

 

Identifying FGFR3 mutations in urothelial cells from voided urine will help in differential diagnosis and management of bladder cancer in combination with other specific tests for bladder cancer. This testing is usually performed in conjunction with Ki67 Immunohistochemistry staining, and Molecular Grade Chart for Prognostic Classification should be used. 

  • As an aid for initial diagnosis of bladder carcinoma in patients with hematuria (symptomatic)
  • Disease monitoring for tumor recurrence in patients previously diagnosed with bladder cancer
  • Differential diagnosis of non-muscle invasive bladder cancer
  • Differential diagnosis of low-grade and early-stage bladder cancer
  • Disease management and therapy adjustment

Positive:

  • A positive for any or more tested mutations would indicate mutation in FGFR3 which might be diagnostic of bladder cancer or bladder cancer recurrence.
  • If FGFR3 is tested in conjunction with Ki67 for prognostic purposes and disease management, then interpretation is based on results from both, and Molecular Grade Chart for Prognostic Classification should be used:

Negative:

  • A negative result is suggestive of the absence of bladder cancer, but does not rule it out.
  • FGFR3 mutations have been associated with up to 80% of non-muscle invasive bladder cancer
  • Studies have shown that the presence of FGFR3 mutations in bladder tumors is associated with low-grade and early-stage bladder cancer
  • Patients with FGFR3 mutations, appear to have better disease-free and progression-tree survival

Molecular Grade FGFR3 and Ki-67 Status Disease Free, Progression Free, Overall Survival mG1 FGFR3 mutation detected and Ki67 Low (<25%) Favorable Prognosis mG2 FGFR3 mutation detected and Ki67 High (>25%) or FGFR3 Normal and Ki67 Low (<25%) Less Favorable Prognosis mG3 FGFR3 Normal and Ki67 High (>25%) Unfavorable Prognosis

Negative for mutations analyzed (No mutation detected)

Polymerase chain reaction (PCR) and Allele Specific Primer Extension (ASPE) using Capillary Electrophoresis, Real-time PCR using sequence specific probes (TaqMan technology), single stranded conformation polymorphism (SSCP) and restriction fragment length polymorphism (RFLP), Sequencing and Next Generation Sequencing.

First voided urine collected in a sterile container. 

Stability

  • Ambient: 1-2 days (transport only)
  • Refrigeration: 7 days
  • Freezing: 1 month
Urinalysis and urine cytology, cystoscopic examination, PSA (total), Nuclear Matrix Proteins (NMP22), UroVysion™ FISH, Ki-67 and p53 Tissue Assay, p21 (Waf1/Cip 1), p16, Cytokeratin 5,6 (CK 5,6) by Immunohistochemistry.
3-7 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login